Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2016

01-10-2016 | Topic Review

Prognostic role of microRNA-21 expression in gliomas: a meta-analysis

Authors: Chao Li, Jianjun Sun, Qian Xiang, Yan Liang, Nan Zhao, Zhuo Zhang, Qianxin Liu, Yimin Cui

Published in: Journal of Neuro-Oncology | Issue 1/2016

Login to get access

Abstract

MicroRNA-21 (miRNA-21) has recently been shown to be a promising prognostic tumor biomarker. However, few studies have not supported this idea and have shown inconsistent data. Thus, we conducted a meta-analysis to elucidate the predictive value of miRNA-21 in gliomas. The relevant studies were identified by performing online search in PubMed, EMBASE and Web of Science databases up to Apr 2016. This meta-analysis study included seven eligible studies, consisting of 1121 gliomas and 533 glioblastoma multiforme (GBM) patients. Heterogeneity between studies was assessed using Egger’s and Begg’s test. Hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS), which compared the expression levels of miRNA-21 in patients with gliomas, were extracted and estimated. Our analysis revealed that the high expression of miRNA-21 is associated with the worse OS in gliomas. Further subgroup analysis indicated that increased expression of miRNA-21 was also associated with OS in GBM patients. Moreover, we observed a correlation between miRNA-21 expression and the World Health Organization defined gliomas grading system (WHO grade). Besides, high miRNA-21 expression was significantly correlated with lowered OS both in the Asian group and non-Asian group. In the cut-off subgroup analysis, both mean cut off value and median cut off value were significantly associated with OS. The expression level of miRNA-21 was not high in low KPS (Karnofsky score) group. miRNA-21 appears to be a promising biomarker for predicting the progression of patients with gliomas or GBM. However, due to the limited sample size, further prospective or retrospective multi-center well designed studies with adequate sample size should be conducted to verify its definite prognostic value.
Literature
1.
2.
Dolecek TA, Propp JM, Stroup NE et al (2012) CBTRUS statistical report: primary brain andcentral nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. doi:10.​1093/​neuonc/​nos218
3.
van den Bent MJ, Kros JM (2007) Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol 66(12):1074–1081PubMedCrossRef
4.
Dellaretti M, Reyns N, Touzet G et al (2012) Diffuse brainstem glioma: prognostic factors: clinical article. J Neurosurg.117(5):810–814PubMedCrossRef
5.
Johnson DR, Galanis E (2013) Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep 15(1):56–63PubMedCrossRef
6.
Kwak HJ, Kim YJ, Chun KR et al (2011) Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30(21):2433–2442PubMedCrossRef
7.
Li WQ, Yu HY, Li YM et al (2014) Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor. Biochem Biophys Res Commun 446(4):1261–1267PubMedCrossRef
8.
9.
Lim LP, Lau NC, Garrett-Engele P et al (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433(7027):769–773PubMedCrossRef
10.
11.
Nana-Sinkam P, Croce CM (2010) MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics 11(5):667–669PubMedCrossRef
12.
13.
Volinia S, Calin GA, Liu CG et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103(7):2257–2261PubMedPubMedCentralCrossRef
14.
15.
Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033PubMedCrossRef
16.
17.
Conti A, Aguennouz M, La Torre D et al (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors. J Neurooncol 93(3):325–332PubMedCrossRef
18.
Ho CY, Bar E, Giannini C, Marchionni L et al (2013) MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol 15(1):69–82
19.
20.
Hermansen SK, Dahlrot RH, Nielsen BS et al (2013) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111(1):71–81PubMedCrossRef
21.
Childs G, Fazzari M, Kung G, Kawachi N et al (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174(3):736–745PubMedPubMedCentralCrossRef
22.
Heneghan HM, Miller N, Kelly R et al (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15(7):673–682PubMedPubMedCentralCrossRef
23.
Song J, Bai Z, Zhang J et al (2013) Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis. Oncol Lett 6:1733–1737PubMedPubMedCentral
24.
25.
26.
27.
Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA 283:2008–2012PubMedCrossRef
28.
29.
Zhi F, Chen X, Wang S et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46(9):1640–1649PubMedCrossRef
30.
Shi R, Wang PY, Li XY et al (2015) Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget 6(29):26971–81PubMedPubMedCentralCrossRef
31.
Louis DN, Ohgaki H, Wiestler OD et al. (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer (IARC), Lyon
32.
33.
Yan LX, Huang XF, Shao Q et al (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11):2348–2360PubMedPubMedCentralCrossRef
34.
Zhang JG, Wang JJ, Zhao F et al (2010) MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411:846–852PubMedCrossRef
35.
Lu Z, Liu M, Stribinskis V et al (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31):4373–4379PubMedCrossRef
36.
Meng F, Henson R, Wehbe-Janek H et al (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647–658PubMedPubMedCentralCrossRef
37.
Zhu S, Si ML, Wu H et al (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19):14328–14336PubMedCrossRef
38.
Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68(19): 8164–8172PubMedCrossRef
39.
Song B, Wang C, Liu J et al (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29:29PubMedPubMedCentralCrossRef
40.
Sarkar J, Gou D, Turaka P et al (2010) MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 299(6):L861–L871PubMedPubMedCentralCrossRef
41.
Iliopoulos D, Jaeger SA, Hirsch HA et al (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39(4):493–506PubMedPubMedCentralCrossRef
42.
Dong Y, Sui L, Yamaguchi F et al (2010) Phosphatase and tensin homolog deleted on chromosome 10 regulates sensory cell proliferation and differentiation of hair bundles in the mammalian cochlea. Neuroscience 170(4):1304–1313PubMedCrossRef
43.
Gao Q, Zhang L, Zhang B et al (2014) Phosphatase and tensin homolog overexpression decreases proliferation and invasion and increases apoptosis in oral squamous cell carcinoma cells. Oncol Lett 8(3):1058–1064PubMedPubMedCentral
44.
Peters JM, Aoyama T, Cattley RC et al (1998) Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis 19(11):1989–1994CrossRef
45.
Gabriely G, Wurdinger T, Kesari S et al (2008 Sep) MicroRNA-21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28(17):5369–5380PubMedPubMedCentralCrossRef
46.
Gu L, Li H, Chen L, Ma X et al (2015) MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget 6(32):32545–32560PubMedPubMedCentral
47.
Wang Y, Zhang Y, Pan C et al (2015) Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis. PLoS One 10(2):e0118647PubMedPubMedCentralCrossRef
48.
Fu C, Dong W, Wang Z et al (2014) The expression of miR-21 and miR-375 predict prognosis of esophageal cancer. Biochem Biophys Res Commun 446(4):1197–1203PubMedCrossRef
49.
50.
Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6:375–392PubMedCrossRef
51.
52.
Metadata
Title
Prognostic role of microRNA-21 expression in gliomas: a meta-analysis
Authors
Chao Li
Jianjun Sun
Qian Xiang
Yan Liang
Nan Zhao
Zhuo Zhang
Qianxin Liu
Yimin Cui
Publication date
01-10-2016
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2233-7

Other articles of this Issue 1/2016

Journal of Neuro-Oncology 1/2016 Go to the issue

Letter to the Editor

Deciphering the real incidence of medulloblastoma with extensive nodularity in adult patients

Clinical Study

Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab

Clinical Study

Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma

Clinical Study

Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database

Laboratory Investigation

Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting

Clinical Study

MR imaging features that distinguish spinal cavernous angioma from hemorrhagic ependymoma and serial MRI changes in cavernous angioma